DEPARTMENT OF AGRICULTURE
Forest Service

Ashley Resource Advisory Committee

AGENCY: Forest Service, USDA.

ACTION: Notice of meeting cancellation.

SUMMARY: The Ashley Resource Advisory Committee (RAC) meeting scheduled on the date below is cancelled. The meeting was scheduled to meet in Vernal, Utah. The RAC is authorized under the Secure Rural Schools and Community Self-Determination Act (the Act) (Pub. L. 110–343) and operates in compliance with the Federal Advisory Committee Act (FACA) (Pub. L. 92–463).

DATES: The cancelled meeting was scheduled for 6:00 p.m. on February 28, 2013.

ADDRESS: The cancelled meeting was to be held at the Ashley National Forest Supervisor’s Office, Conference Room, 355 North Vernal Avenue, Vernal, Utah. Written comments concerning this cancellation may be submitted as described under FOR FURTHER INFORMATION CONTACT.

FOR FURTHER INFORMATION CONTACT: Louis Haynes, RAC Coordinator, by phone at 435–781–5105 or email at lhaynes@fs.fed.us.

Individuals who use telecommunication devices for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339 between 8:00 a.m. and 8:00 p.m., Eastern Standard Time, Monday through Friday.

Dated: November 5, 2013.

John R. Erickson, Forest Supervisor.

INFORMATION CONTACT

Written comments concerning this meeting cancellation are invited. Please submit written comments to Louis Haynes, RAC Coordinator, by mail at Ashley National Forest Supervisor’s Office, Conference Room, 355 North Vernal Avenue, Vernal, Utah 84078, or email at lhaynes@fs.fed.us.

Any party having a substantial interest in these proceedings may request a public hearing on the matter. A written request for a hearing must be submitted to the Trade Adjustment Assistance for Firms Division, Room 71030, Economic Development Administration, U.S. Department of Commerce, Washington, DC 20230, no later than ten (10) calendar days following publication of this notice.

Please follow the requirements set forth in EDA’s regulations at 13 CFR 315.9 for procedures to request a public hearing. The Catalog of Federal Domestic Assistance official number and title for the program under which these petitions are submitted is 11.313, Trade Adjustment Assistance for Firms.

LIST OF PETITIONS RECEIVED BY EDA FOR CERTIFICATION ELIGIBILITY TO APPLY FOR TRADE ADJUSTMENT ASSISTANCE

<table>
<thead>
<tr>
<th>Firm name</th>
<th>Firm address</th>
<th>Date accepted for investigation</th>
<th>Product(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DryCase, LLC</td>
<td>349 Military Cutoff Road, Wilmington, NC 28405.</td>
<td>11/08/2013</td>
<td>The firm manufactures waterproof bags</td>
</tr>
<tr>
<td></td>
<td>1521 East McFadden Suite F, Santa Ana, CA 92705.</td>
<td></td>
<td>for electronic devices.</td>
</tr>
<tr>
<td>Benchmark Clothing Company, Inc.</td>
<td></td>
<td>11/08/2013</td>
<td>The firm manufactures flame resistant</td>
</tr>
<tr>
<td>(dba—Benchmark Clothing and</td>
<td></td>
<td></td>
<td>garments.</td>
</tr>
<tr>
<td>Benchmark FR)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DEPARTMENT OF COMMERCE

Foreign Trade Zones Board

[B–98–2013]

Foreign-Trade Zone (FTZ) 93—Raleigh/ Durham, North Carolina; Notification of Proposed Production Activity; GlaxoSmithKline, PLC (Pharmaceutical Products); Zebulon, North Carolina

The Triangle J Council of Governments, grantee of FTZ 93, submitted a notification of proposed production activity to the FTZ Board on behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon, North Carolina. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on November 18, 2013.

The GlaxoSmithKline facility is located within Site 6 of FTZ 93. The facility is used for the production and packaging of pharmaceutical products. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited to the specific foreign-status materials and components and specific finished products listed in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt GlaxoSmithKline from...
customs duty payments on the foreign status components used in export production. On its domestic sales, GlaxoSmithKline would be able to choose the duty rates during customs entry procedures that apply to inhalers, tablets, and capsules which treat a variety of medical conditions (duty rates range from free to 6.4%) for the foreign status inputs noted below. Customs duties also could possibly be deferred or reduced on foreign status production equipment.

The finished products include devices such as respiratory placebo inhalers, Relenza anti-viral inhalers, Seretide/Advair, Serevent and Flovent diskit respiratory inhalers, Advair and Ventolin HFA respiratory inhalers, and the following tablets and capsules—Lovaza anti-hyperlipidemic, Paxil depression, Avandamet metabolic, Avandary metabolic, Avandia metabolic, Lamictal central nervous system (CNS), Potiga CNS, Amger CNS, Horizont CNS, Imitrex CNS, Lamictal ODT CNS, Requip/Requip XL CNS, Treximet CNS, Telzir anti-viral, Valtrex anti-viral, Zovirax anti-viral, Wellbutrin/Buproprion depression, Zantac gastrointestinal (GI), Zofran GI, Votrient urology, Coreg CR cardiovascular, Rythmol cardiovascular, Innopran XL hypertension, Jalyn urology, Avodart urology, Lanoxin cardiovascular, Malaroan anti-malarial, Promacta immune thrombocytopenia (ITP), and Tykerb oncology.

The components and materials sourced from abroad include corn starch, lactose monohydrate, fluticasone/salmeterol placebo diskus (a type of inhaler), respiratory placebo inhaler, silica colloidal anhydrous, precipitated calcium carbonate, pharmaceutical talc, zephex 134a propellant, mannitol, magnesium stearate, stearic acid, potassium sorbate, propafenon hcl, bupropion hydrochloride, melphalan, albuterol sulfate, salbuterol sulfate, salmeterol, vilanterol trifenatate, umclidinum api, paracetamol, ezogabine (retigabine), paracetamol, metformin hydrochloride, ranitidine hydrochloride, zanamivir, ondansetron hydrochloride, abacavir sulfate, valacyclovir hydrochloride, lamotrigine, rosiglitazone maleate, paroxetine hydrochloride, lamivudine, zidovudine, pazopanib, fluticasone propionate, fluticasone furoate, dutasteride, Lovaza capsules, brem allotopic inhalers, avodart capsules, flovent diskus, Paxil tablets, lexiva oral suspension, sumatriptan succinate/naproxen (Treximet), abacavir/lamivudine tablets [epzicom] tablets, atovaquone and proguanil hcl tablets, combivir tablets, duloxetine tablets, epivir tablets, epzicom tablets, malarone tablets, zidagen tablets, Zantac tablets, mekinist tablets, tretinoin tablets, pazopanib tablets, tafinlar capsules, vortrient tablets, coreg cr capsules, flolan for injection, propafenon sr, Rythmol (proafenon) sr, Amger tablets, imigran injection, imitrex bulk pack, sumatriptan succinate 85mg/naproxen, lamictal, pantane tablets, ondansetron odt bulk, requip tablets, sotiatane (acetretin) capsules, Zofran, Ventolin actuator dose counter, Advair diskus, Advair diskus inhalation powder, fluticasone/salmeterol aerosol inhalers, Ventolin samples, Seretide, argatroban, arixtra, Avandamet tablets, Avandia tablets, dutasteride-tamsulosin hcl fdc capsules, eltrombopag, flolan sterile diluent, Jalyn fixed dose combination capsules, panadol tablets, opadyr (an excipient), starch pregel, Avandamet placebo tablets, placebo diskus, nasal spray demo pack, respiratory placebo, triacetin, crosopovidone, povidone, spectracel, alginic acid ep, 20 micron aluminum powder, empty aerosol cans, pressure can spray valves, diskus subassemblies, multi-dose powder inhalers, novel dry powder inhalers, multi-dose powder inhaler subassembly and placebo, multi-dose powder inhaler diskus devices, actuators—and their dose counters and assemblies (duty rates range from free to 6.5%).

Public comment is invited from interested parties. Submissions shall be addressed to the FTZ Board’s Executive Secretary at the address below. The closing period for their receipt is January 6, 2014.

A copy of the notification will be available for public inspection at the Office of the Executive Secretary, Foreign-Trade Zones Board, Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., Washington, DC 20230–0002, and in the “Reading Room” section of the FTZ Board’s Web site, which is accessible via www.trade.gov/ftz.

For further information, contact Diane.Finver@trade.gov or (202) 482–1367.

Dated: November 19, 2013.
Andrew McGilvray, Executive Secretary.